ACL Stock Overview
Provides pathology diagnostic services in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
Australian Clinical Labs Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$3.47 |
| 52 Week High | AU$3.86 |
| 52 Week Low | AU$2.14 |
| Beta | 1.15 |
| 11 Month Change | -3.88% |
| 3 Month Change | 22.61% |
| 1 Year Change | 35.55% |
| 33 Year Change | -17.97% |
| 5 Year Change | n/a |
| Change since IPO | 1.46% |
Recent News & Updates
Why Investors Shouldn't Be Surprised By Australian Clinical Labs Limited's (ASX:ACL) 29% Share Price Surge
Sep 03
Should You Think About Buying Australian Clinical Labs Limited (ASX:ACL) Now?
Sep 02Recent updates
Why Investors Shouldn't Be Surprised By Australian Clinical Labs Limited's (ASX:ACL) 29% Share Price Surge
Sep 03Should You Think About Buying Australian Clinical Labs Limited (ASX:ACL) Now?
Sep 02We Think Australian Clinical Labs (ASX:ACL) Is Taking Some Risk With Its Debt
Jun 20Are Investors Undervaluing Australian Clinical Labs Limited (ASX:ACL) By 46%?
Feb 21Is It Time To Consider Buying Australian Clinical Labs Limited (ASX:ACL)?
Dec 08Here's Why We Think Australian Clinical Labs (ASX:ACL) Might Deserve Your Attention Today
Aug 14Australian Clinical Labs Limited (ASX:ACL) Just Reported Half-Year Earnings: Have Analysts Changed Their Mind On The Stock?
Feb 25New Forecasts: Here's What Analysts Think The Future Holds For Australian Clinical Labs Limited (ASX:ACL)
Dec 22The Market Lifts Australian Clinical Labs Limited (ASX:ACL) Shares 31% But It Can Do More
Dec 21The Strong Earnings Posted By Australian Clinical Labs (ASX:ACL) Are A Good Indication Of The Strength Of The Business
Sep 01Shareholder Returns
| ACL | AU Healthcare | AU Market | |
|---|---|---|---|
| 7D | -2.0% | 0.7% | 1.5% |
| 1Y | 35.5% | 4.0% | 17.2% |
Return vs Industry: ACL exceeded the Australian Healthcare industry which returned 4% over the past year.
Return vs Market: ACL exceeded the Australian Market which returned 17.2% over the past year.
Price Volatility
| ACL volatility | |
|---|---|
| ACL Average Weekly Movement | 5.0% |
| Healthcare Industry Average Movement | 5.1% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 17.3% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: ACL has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: ACL's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 4,900 | Melinda McGrath | www.clinicallabs.com.au |
Australian Clinical Labs Limited provides pathology diagnostic services in Australia. The company offers range of services, which include routine pathology test, advanced molecular genetics testing, harmony NIPT and first trimester screening, genetic carrier screening, chemical pathology, histopathology, and cytopathology; hematology, allergy, and immunology; serology and microbiology; and infectious molecular testing, cardiac testing services, functional pathology, veterinary pathology, and commercial drug and alcohol testing services. It offers its service to private and public hospitals.
Australian Clinical Labs Limited Fundamentals Summary
| ACL fundamental statistics | |
|---|---|
| Market cap | AU$682.41m |
| Earnings (TTM) | AU$23.93m |
| Revenue (TTM) | AU$696.37m |
28.9x
P/E Ratio1.0x
P/S RatioIs ACL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACL income statement (TTM) | |
|---|---|
| Revenue | AU$696.37m |
| Cost of Revenue | AU$442.37m |
| Gross Profit | AU$254.00m |
| Other Expenses | AU$230.07m |
| Earnings | AU$23.93m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Feb 26, 2025
| Earnings per share (EPS) | 0.12 |
| Gross Margin | 36.48% |
| Net Profit Margin | 3.44% |
| Debt/Equity Ratio | 31.0% |
How did ACL perform over the long term?
See historical performance and comparison